drug_type
RELEVANT_DRUG
intervention_type
Cellular immunotherapy (CAR T cells)
drug_description
Autologous, gene-modified T cells engineered ex vivo to express a chimeric antigen receptor targeting a plasma cell surface antigen; upon infusion, they enable MHC-independent recognition and killing of malignant plasma cells via T-cell activation, expansion, cytokine release, and perforin/granzyme-mediated cytotoxicity in relapsed/refractory multiple myeloma and plasma cell leukemia.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intravenous
drug_mechanism_of_action
Autologous T cells are gene‑modified ex vivo to express a chimeric antigen receptor that binds a plasma cell surface antigen, enabling MHC‑independent recognition of malignant plasma cells. After infusion, CAR signaling activates and expands the T cells, induces cytokine release, and drives perforin/granzyme‑mediated cytotoxic killing of multiple myeloma/plasma cell leukemia cells.
drug_name
CT0596 CAR-T cells
nct_id_drug_ref
NCT06718270